Compare
Foundayo vs. Zepbound

Foundayo (orforglipron) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist. It's approved for weight loss in certain adults. This medication is meant to be used together with a reduced-calorie diet and exercise. Foundayo (orforglipron) comes as tablets and is taken by mouth once a day with or without food. The dose is slowly raised over several weeks. Common side effects include nausea, constipation, and diarrhea.

• Weight loss and long-term weight management in adults who are considered obese or overweight with at least one weight-related condition

• Nausea (26-35%)
• Constipation (20-27%)
• Diarrhea (21-25%)
• Vomiting (13-24%)
• Indigestion (12-16%)
• Stomach pain (13-14%)
• Headache (8-9%)
• Bloating (7-9%)
• Feeling tired (6-9%)
• Belching (6-8%)
• Gastroesophageal reflux disease (GERD; 6-7%)
• Having a lot of gas (5-6%)
• Hair loss (4-5%)

• Possible risk of thyroid cancer
• Severe stomach side effects
• Kidney damage
• Inflammation of the pancreas (pancreatitis)
• Gallbladder problems
• Low blood sugar
• Allergic reactions
• Eye problems in people with Type 2 diabetes (diabetic retinopathy)
• Lung problems during general anesthesia or deep sedation

Zepbound (tirzepatide) is an injectable medication that's used along with diet and exercise. It helps with weight loss in adults who meet criteria for weight management therapy. It's also approved to treat moderate-to-severe sleep apnea. This medication belongs to the drug class called GIP and GLP-1 agonists. The dosage is 1 injection under the skin once a week. Common side effects include nausea, diarrhea, and injection site reactions. Zepbound (tirzepatide) is only available as a brand-name medication.

In addition to a balanced diet and exercise plan:

• Weight loss and long-term weight management in adults considered obese or overweight with at least one weight-related condition (e.g., high blood pressure, Type 2 diabetes)
• Moderate-to-severe obstructive sleep apnea (OSA) in adults considered obese

• Nausea (25-29%)
• Diarrhea (19-23%)
• Constipation (11-17%)
• Vomiting (8-13%)
• Stomach pain (9-10%)
• Indigestion (9-10%)

• Risk of thyroid cancer
• Stomach problems
• Kidney damage
• Gallbladder problems
• Inflammation of the pancreas (pancreatitis)
• Allergic reactions
• Low blood sugar (hypoglycemia)
• Eye problems in people with Type 2 diabetes (diabetic retinopathy)
• Lung problems during general anesthesia or deep sedation
• Don't share Zepound KwikPens with anyone